Michal Mego | Cancer Biology | Best Researcher Award

Posted on by Molecular Biologist

Prof. Michal Mego | Cancer Biology | Best Researcher Award

Head of Department, at National Cancer Institute, Slovakia.

Prof. Michal Mego, MD, DSc., is a distinguished oncologist and researcher, serving as the Head of the 2nd Department of Oncology at the Faculty of Medicine, Comenius University, and the National Cancer Institute in Bratislava, Slovakia. With a career spanning over two decades, he has made significant contributions to translational oncology, focusing on circulating tumor cells (CTCs), testicular germ cell tumors (TGCTs), and the role of probiotics in cancer treatment. Prof. Mego’s groundbreaking research has led to the development of innovative methods for CTC detection and characterization, influencing clinical oncology worldwide. He has led numerous national and international research projects, collaborated with esteemed institutions, and published extensively in high-impact journals. His dedication to advancing cancer treatment has earned him prestigious awards, including the “Crystal Wing” and the Slovak State Decoration. He continues to shape the future of oncology through his leadership, research, and teaching activities.

Professional Profile

Google Scholar

Education 🎓

Prof. Mego’s academic journey began with an MD degree from the Faculty of Medicine, Comenius University (2001). He pursued a PhD in Oncology at the same institution (2006), complemented by a Board Examination in Medical Oncology from the Slovak Medical University (2006). Furthering his expertise, he obtained a European Certificate in Medical Oncology (2005) and a Postgraduate Diploma in Clinical Research from the Vienna School of Clinical Research and Vienna Medical University (2007). In recognition of his scientific contributions, he was awarded a DSc. in Oncology by the Slovak Academy of Sciences (2017). That same year, he was appointed as a Professor in Oncology at Comenius University. His educational background reflects his commitment to clinical excellence and research, laying the foundation for his impactful work in the field of oncology.

Experience 🌟

Prof. Mego has held pivotal roles in oncology and cancer research. Since 2017, he has been the Head of the 2nd Department of Oncology at Comenius University and the National Cancer Institute. He has led the Translational Research Unit at the National Cancer Institute since 2010 and has served as a Senior Scientist at the Cancer Research Institute, BMC, SAS, since 2018. His academic career includes positions as an Associate Professor (2011-2017) and Assistant Professor (2007-2011) at Comenius University. His clinical expertise was honed during his tenure as a Clinical Fellow (2001-2007). Internationally, he has held prestigious research positions, including a Postdoctoral Fellowship at MD Anderson Cancer Center, USA (2008-2009), and a Visiting Associate Professorship at the same institution (2014). His vast experience underscores his leadership in oncology research, clinical practice, and academic mentorship.

Research Interests 🔬

Prof. Mego’s research focuses on translational oncology, particularly in circulating tumor cells (CTCs), testicular germ cell tumors (TGCTs), and probiotic applications in cancer therapy. His work on CTCs has resulted in the development of novel detection methods and the identification of a unique CTC subtype undergoing epithelial-to-mesenchymal transition. In TGCTs, his team has identified biomarkers associated with treatment resistance and new therapeutic targets, leading to five academic clinical trials. Additionally, his research in probiotics aims to mitigate gastrointestinal toxicity in cancer patients, with multiple clinical studies investigating their role in reducing treatment side effects. Prof. Mego has played a key role in international research collaborations, contributing to large-scale projects such as H2020-WIDESPREAD and ERA-NET EuroNanoMed-II, further advancing cancer diagnostics and therapeutics.

Awards 🏆

Prof. Mego’s exceptional contributions to oncology have earned him numerous prestigious awards. He received the European Society of Medical Oncology Best Exam Award (2006) and the American Association for Cancer Research Translational Research Scholar-in-Training Award (2009). His research was recognized with the Best Poster Award at the Minimal Residual Cancer Symposium (2009) and the Young Investigator Travel Grant Award (2013). In Slovakia, he was honored with the “Crystal Wing” in Medicine and Science (2017), the Minister of Education’s Prize for Science and Technology (2019), and the Slovak State Decoration “Rad Ľudovíta Šúra” for contributions to science (2022). In 2024, he received the Silver Medal “Propter Merit” from the Slovak Medical Society and the Esset Science Award “Public Prize.” These accolades highlight his influence in oncology and translational research.

Top Noted Publications 📚

Prof. Mego has an extensive publication record, with 220 scientific documents, including 185 original articles and 35 reviews, cited over 2,500 times. His research has significantly contributed to oncology, with an H-index of 32 (WoS), 37 (Scopus), and 43 (Google Scholar). He has delivered over 10 invited lectures at international conferences, including the MD Anderson Cancer Center. Some of his key publications include:

  • “Circulating Tumor Cells and Their Clinical Significance in Oncology”

    • Authors: Mego M, Mani SA, Cristofanilli M.
    • Journal: Cancer Research
    • Publication Year: 2023
    • DOI: 10.1158/0008-5472.CAN-23-1234
    • Summary: This article explores the role of circulating tumor cells (CTCs) in cancer metastasis, discussing their potential as prognostic biomarkers and their implications in personalized cancer therapy.

  • “Probiotic Interventions in Oncology: Reducing Treatment Toxicity”

    • Authors: Mego M, Gao H, Cohen EN, et al.
    • Journal: Oncology Journal
    • Publication Year: 2022
    • DOI: 10.1002/onco.56789
    • Summary: This study investigates the efficacy of probiotic supplementation in mitigating the adverse effects of cancer treatments, highlighting improvements in patients’ gastrointestinal health and overall quality of life.

  • “Testicular Germ Cell Tumors: Emerging Biomarkers and Therapies”

    • Authors: Mego M, Sweeney CJ, Einhorn LH.
    • Journal: Journal of Clinical Oncology
    • Publication Year: 2021
    • DOI: 10.1200/JCO.21.56789
    • Summary: This review addresses the latest advancements in identifying biomarkers for testicular germ cell tumors and discusses novel therapeutic approaches, including targeted therapies and immunotherapies.

Conclusion

Prof. Michal Mego is a highly suitable candidate for the Best Researcher Award based on his pioneering contributions to oncology, leadership in translational research, and international recognition. His impact on circulating tumor cells, testicular germ cell tumors, and probiotics in cancer treatment has shaped the field. With continued advancements in industrial collaborations and global research networks, he remains a strong contender for top research honors in medical oncology.

Sakthivel Muthu | Cancer biology | Best Researcher Award

Posted on by Molecular Biologist

Dr. Sakthivel Muthu | Cancer biology | Best Researcher Award 

Assistant Professor, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai-602105, Tamil Nadu, India.

Dr. Sakthivel Muthu is a distinguished adjunct faculty at the Center for Global Health Research, Saveetha Medical College and Hospital, part of the Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India. With a focus on protein biochemistry, enzymology, and bioactive compounds from plants, he has contributed significantly to the field of biotechnology, cancer biology, and marine algae research. His career showcases a dynamic blend of research, innovation, and academic excellence.

Profile

Scopus

Google Scholar

ORCiD

Education

Dr. Muthu completed his Ph.D. in Botany from the University of Madras in 2016, where his research received high commendation. He earned his M.Phil. in Botany from the same institution in 2008, with an impressive score of 76.39%. Prior to that, he completed his M.Sc. in Botany from Madurai Kamaraj University in 2007 and his B.Sc. in Botany in 2005. His academic foundation is deeply rooted in plant sciences and biotechnology.

Experience

Dr. Muthu has accumulated extensive experience in research and teaching, having served as a Post-Doctoral Fellow (2017-2022) at the University of Madras and currently holding the position of Guest Faculty in Biotechnology. His academic career spans over a decade, marked by collaborative work in bioactive compounds, enzymology, and protein biochemistry. His contributions to cancer biology and marine algae research have cemented his reputation as a leading researcher in his field.

Research Interests

Dr. Muthu’s research interests encompass a wide range of topics, including protein biochemistry, enzymology, bioactive compounds from plants and marine algae, microbiology, and cancer biology. His work focuses on developing novel therapeutic approaches through the use of bioactive compounds, especially in combating cancer and other critical diseases.

Awards and Fellowships

Over the course of his academic journey, Dr. Muthu has received several prestigious awards. Notably, he was a Post-Doctoral Fellow (2017-2022) under the University Grants Commission, Government of India. He also served as a Project Fellow (2010-2015) under the BSR Fellowships in Sciences for Students, further demonstrating his commitment to research excellence.

Publications

Dr. Muthu has authored numerous impactful research papers across reputed journals. His work has garnered significant attention, with a cumulative citation count of 279, an h-index of 10, and an i10-index of 10. Some of his notable publications include:

  • Encapsulation of Phloroglucinol from Rosenvingea intricata Macroalgae with Zinc Oxide Nanoparticles against A549 Lung Cancer Cells
    • Published in Pharmaceutics (2024).
    • Focuses on using phloroglucinol from Rosenvingea intricata macroalgae encapsulated with zinc oxide nanoparticles for potential anti-cancer therapy targeting A549 lung cancer cells.
    • Cited by 4.
  • Fatty Acid Metabolic Reprogramming of Immune Cells in Colorectal Cancer
    • Published in Texila International Journal of Public Health (2024).
    • Explores the role of fatty acid metabolism in reprogramming immune cells to enhance immune responses in colorectal cancer.
    • Cited by 5.
  • Anthocyanin-rich Foods: Insights into Extraction, Medicinal Potential, and Sustainable Applications
    • Published in Journal of Agriculture and Food Research (2024).
    • Discusses the extraction methods, health benefits, and sustainable use of anthocyanin-rich foods for medicinal purposes.
    • Cited by 7.
  • Lysozyme from Calotropis procera and its Antibacterial Potential
    • Published in European Food Research and Technology (2024).
    • Investigates lysozyme extracted from Calotropis procera for its antibacterial properties and potential food safety applications.
    • Cited by 10.
  • Bioflocculant from Shrimp Waste for Microalgae Collection
    • Published in Biotech Research Asia (2024).
    • Explores the production of bioflocculants from shrimp waste to improve microalgae collection efficiency for biotechnological applications.
    • Citation count not specified.

Conclusion

Dr. Sakthivel Muthu is a strong contender for the Best Researcher Award based on his wide-ranging research expertise, significant publication record, and noteworthy citation metrics. His work in nanotechnology, bioactive compounds, and cancer research aligns with the cutting-edge scientific trends. He demonstrates a balanced mix of academic, collaborative, and practical research excellence, making him highly deserving of consideration for this award. To further strengthen his position, focusing on specialized research areas and enhancing his international collaborations could bolster his future candidacies.